Compare AbbVie Inc (ABBV) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Monolithic Power Systems Inc — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Monolithic Power Systems Inc trades at $1,312.11 (market cap $62.53B). The key difference: AbbVie Inc is far larger — about 7.2× Monolithic Power Systems Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | MPWR | |
|---|---|---|
Market Cap | $449.91B | $62.53B |
Sector | Health | Utilities |
52-Week High | $261.07 | $1.69K |
52-Week Low | $184.85 | $711.24 |
Enterprise Value | $513.38B | $61.19B |
Dividend Yield | 2.72% | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
MPWR trades at $1,346.13, up 4.5% in the past 24 hours, showing strong momentum. The stock exhibits bearish technical signals but benefits from consistent earnings beats and robust profitability, with a net margin of 22.98%. Recent news highlights growth in AI infrastructure and consumer electronics demand. Cash flow remains positive, and a $2.00 dividend is scheduled for July 2026.
Outlook is supported by analyst optimism (88% buy ratings) and a consensus price target of $1,760, though high valuation multiples and ongoing legal investigations pose risks. Revenue growth and AI-driven demand present opportunities, but investors should weigh elevated P/E of 96.36 against potential market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
